KNTE Projected Dividend Yield

Kinnate Biopharma Inc ( NASDAQ : KNTE )

Kinnate is a clinical stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for genomically defined cancers. Co.'s focus is on three patient populations: those with cancers that harbor known oncogenic drivers with no available targeted therapies; those with genomically well-characterized tumors that have resistance to available treatments; and those whose tumors have acquired resistance over the course of therapy to available treatments. Co.'s product candidates are KIN002787, which is for the treatment of patients with lung cancer, melanoma and other solid tumors; and KIN-3248, which is targeting cancer-associated alterations in FGFR2.

20 YEAR PERFORMANCE RESULTS